Universal newborn hearing screening is a widely-adopted clinical practice and mandated by law in the United States. Current physiology-based hearing screening protocol generates high false positive rate and is unable to detect early-onset hearing loss and provide a diagnosis that defines underlying etiology. Studies have indicated that the primary diagnostic concern in congenital hearing loss is genetic mutations in deafness genes and infections with cytomegalovirus. Recent advances in massively-parallel sequencing technologies have made it possible to routinely analyze targeted sets of human genes totaling millions of base pairs. However, the new technology has not been validated with deafness genes. More importantly, the high cost associated with capturing targeted deafness genes makes it unlikely that these technological advances will be translated into a widely-adopted clinical tool. The R21 phase of the project will test and validate the core technology for a low-cost approach to efficiently capture exons of most common deafness genes and its suitability for coupling with various types of downstream sequencing applications by massively parallel sequencers for the detection of genetic mutations. In the R33 phase we will expand the capturing coverage of our custom genechips to include all confirmed deafness genes and deafness gene candidates. The overall goal of the project is to provide a cost-competitive and mature implementation protocol for a DNA-based approach for hearing screening that will significantly enhance the current universal newborn hearing screening program.

Public Health Relevance

Recent advances in massively-parallel sequencing technologies have made it possible to routinely analyze targeted sets of human genes totaling millions of base pairs. However, the new technology has not been validated with deafness genes and the high cost associated with capturing targeted deafness genes makes it unlikely that these technological advances will be translated into a widely-adopted clinical tool. This project will test and validate the core technology for a low-cost approach to efficiently capture exons of all confirmed deafness genes and deafness gene candidates. The overall goal of the project is to provide a DNA-based hearing screening method that will significantly enhance the current universal newborn hearing screening program.

Agency
National Institute of Health (NIH)
Institute
National Institute on Deafness and Other Communication Disorders (NIDCD)
Type
Exploratory/Developmental Grants Phase II (R33)
Project #
5R33DC010476-04
Application #
8322001
Study Section
Special Emphasis Panel (ZRG1-ETTN-H (51))
Program Officer
Watson, Bracie
Project Start
2009-09-25
Project End
2014-08-31
Budget Start
2012-09-01
Budget End
2013-08-31
Support Year
4
Fiscal Year
2012
Total Cost
$533,429
Indirect Cost
$157,346
Name
Emory University
Department
Otolaryngology
Type
Schools of Medicine
DUNS #
066469933
City
Atlanta
State
GA
Country
United States
Zip Code
30322
Yuan, Yongyi; Gao, Xue; Huang, Bangqing et al. (2016) Phenotypic Heterogeneity in a DFNA20/26 family segregating a novel ACTG1 mutation. BMC Genet 17:33
Gao, Xue; Huang, Sha-Sha; Yuan, Yong-Yi et al. (2015) Targeted gene capture and massively parallel sequencing identify TMC1 as the causative gene in a six-generation Chinese family with autosomal dominant hearing loss. Am J Med Genet A 167:2357-65
Gao, Xue; Wang, Guo-Jian; Yuan, Yong-Yi et al. (2014) Novel compound heterozygous mutations in MYO7A Associated with Usher syndrome 1 in a Chinese family. PLoS One 9:e103415
Yu, Q; Wang, Y; Chang, Q et al. (2014) Virally expressed connexin26 restores gap junction function in the cochlea of conditional Gjb2 knockout mice. Gene Ther 21:71-80
Yuan, Yongyi; Zhang, Jianguo; Chang, Qing et al. (2014) De novo mutation in ATP6V1B2 impairs lysosome acidification and causes dominant deafness-onychodystrophy syndrome. Cell Res 24:1370-3
Wang, Yunfeng; Sun, Yu; Chang, Qing et al. (2013) Early postnatal virus inoculation into the scala media achieved extensive expression of exogenous green fluorescent protein in the inner ear and preserved auditory brainstem response thresholds. J Gene Med 15:123-33
Lin, Lan; Wang, Yun-Feng; Wang, Shu-Yi et al. (2013) Ultrastructural pathological changes in the cochlear cells of connexin 26 conditional knockout mice. Mol Med Rep 8:1029-36
Angeli, Simon; Lin, Xi; Liu, Xue Zhong (2012) Genetics of hearing and deafness. Anat Rec (Hoboken) 295:1812-29
Yu, Qing; Chang, Qing; Liu, Xia et al. (2012) 7,8,3'-Trihydroxyflavone, a potent small molecule TrkB receptor agonist, protects spiral ganglion neurons from degeneration both in vitro and in vivo. Biochem Biophys Res Commun 422:387-92
Lin, Xi; Tang, Wenxue; Ahmad, Shoeb et al. (2012) Applications of targeted gene capture and next-generation sequencing technologies in studies of human deafness and other genetic disabilities. Hear Res 288:67-76

Showing the most recent 10 out of 13 publications